NEW ANTIDIABETICS AND PERSPECTIVES IN CHRONIC HYPERGLYCEMIA MANAGEMENT
DOI:
https://doi.org/10.51473/rcmos.v1i1.2024.613Keywords:
Combined Modality Therapy. Diabetes Mellitus, Type 2. Disease Prevention. Hyperglycemia. Hypoglycemic Agents.Abstract
The management of type 2 diabetes mellitus (T2DM) has evolved with the emergence of new
oral and subcutaneous antidiabetic agents, which aim not only at glycemic control but also at
the prevention of systemic complications. This study reviews the effects of new classes of
hypoglycemic agents, such as SGLT-2 inhibitors, GLP-1 agonists, and insulin analogs, on
chronic hyperglycemia control and complication prevention. An integrative literature review
was conducted using the PubMed database, with articles published between 2019 and 2024,
selected using the search key: ‘novel antidiabetic drugs’ OR ‘SGLT-2 inhibitors’ AND
‘chronic hyperglycemia’. Clinical trials and systematic reviews with full text in English were
included. SGLT-2 inhibitors were found to be effective in reducing cardiovascular and renal
events, along with a significant improvement in glycemic control. GLP-1 agonists and new
combination therapies also demonstrated reductions in HbA1c levels and improvements in the
risk profile for complications such as cardiovascular disease, diabetic nephropathy, and
retinopathy. The inclusion of new devices, such as smart pens, has also contributed to
individualized patient management. The introduction of new antidiabetic agents, with
innovative mechanisms of action, has brought a significant advancement in the treatment of
T2DM patients, aiding in complication prevention and optimizing glycemic control. The
continued evolution of these therapies promises new perspectives in disease management.
Downloads
References
FERRANNINI, Ele et al. Fixed‐ratio combination of insulin glargine plus lixisenatide (iGlarLixi) improves
ß‐cell function in people with type 2 diabetes. Diabetes, Obesity and Metabolism, v. 24, n. 6, p. 1159-1165,
FUKUNAGA, Kensaku et al. A pilot study on the efficacy of a diabetic diet containing the rare sugar d-allulose
in patients with type 2 diabetes mellitus: a prospective, randomized, single-blind, crossover study. Nutrients, v.
, n. 12, p. 2802, 2023.
GALINDO, Rodolfo J. et al. Efficacy of a smart insulin pen cap for the management of patients with
uncontrolled type 2 diabetes: a randomized cross-over trial. Journal of diabetes science and technology, v. 17,
n. 1, p. 201-207, 2023.
HUSSAIN, Mazhar et al. Comparison Of Efficacy And Safety Profile Of Empagliflozin Versus Dapagliflozin As
Add On Therapy In Type 2 Diabetic Patients. Journal of Ayub Medical College Abbottabad-Pakistan, v. 33,
n. 4, 2021.
KHAN, Asima et al. Comparison of empagliflozin and vildagliptin for efficacy and safety in type 2 diabetes
mellitus in the Pakistani population. Frontiers in Endocrinology, v. 13, p. 926633, 2022.
KIM, Da-Som et al. Efficacy and safety of Omija (Schisandra chinensis) extract mixture on the improvement of
hyperglycemia: A randomized, double-blind, and placebo-controlled clinical trial. Nutrients, v. 14, n. 15, p.
, 2022.
PANIGRAHI, Antarmayee; MOHANTY, Susant. Efficacy and safety of HIMABERB® Berberine on glycemic
control in patients with prediabetes: double-blind, placebo-controlled, and randomized pilot trial. BMC
Endocrine Disorders, v. 23, n. 1, p. 190, 2023.
TRICÒ, Domenico et al. Early time-restricted carbohydrate consumption vs conventional dieting in type 2
diabetes: a randomised controlled trial. Diabetologia, v. 67, n. 2, p. 263-274, 2024.
Downloads
Additional Files
Published
Issue
Section
License
Copyright (c) 2024 Luiza Higino Cruz, Bernardo Viegas Coelho, Felipe Menezes Andrade, Lucas Júnio da Silva (Autor/in)
This work is licensed under a Creative Commons Attribution 4.0 International License.
This work is licensed under the Creative Commons Attribution 4.0 International License (CC BY 4.0). This means you are free to:
- Share — copy and redistribute the material in any medium or format.
- Adapt — remix, transform, and build upon the material for any purpose, even commercially.
The use of this material is conditioned upon proper attribution to the original author(s), providing a link to the license, and indicating if changes were made. The license does not require permission from the author or the publisher as long as these conditions are met.
The Creative Commons license logo is displayed permanently in the footer of the journal.
The copyright of the manuscript can be retained by the authors without restrictions and can be requested at any time, even after publication in the journal.
How to Cite
